Sugi Predict

Sugi Predict / Compounds / SCHEMBL907413

SCHEMBL907413

SCHEMBL907413

CN1CCN(CC(=O)O)C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 3/20 0.51
▸ CYP2C19 P33261 3/20 0.51
▸ CYP2C9 P11712 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ CYP3A4 P08684 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ RECQL P46063 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ACE P12821 4/20 0.41
▸ PER2 O15055 1/20 0.35
▸ CRY2 Q49AN0 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL908747 0.88 LMNA (0.45) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL19962102 0.84 CYP2D6 (0.66) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL12037127 0.79 CYP2D6 (0.56) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL15565060 0.78 ALDH1A1 (0.47) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL12535259 0.78 LMNA (0.39) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL7077964 0.76 — —
SCHEMBL2865650 0.75 CYP2D6 (0.50) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL3591635 0.74 PLA2G10 (0.49) CYP2D6CYP2C19CYP2C9KMT2APOLB
SCHEMBL1446354 0.74 PER2 (0.37) KMT2APOLBLMNAKDM4ERECQL
Hydrogen Peroxide SCHEMBL28763582 0.74 BRD4 (0.39) KMT2AMEN1MAPK1ACEPER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 — — US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 — — US disclosed
CN-112979631-B PARG inhibiting compounds 癌症研究科技有限公司 2024-09-20 — — CN disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 — — US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 — — EP disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 — — EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 — — EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 — — EP disclosed
CN-112979631-A PARG inhibiting compounds 癌症研究科技有限公司 2021-06-18 — — CN disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 — — US disclosed
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators MERCK SHARP & DOHME CORP. 2010-11-11 — — US disclosed
WO-2009124166-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
WO-2009123870-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
WO-2009124166-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2009-10-08 — — US disclosed
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2009-10-08 — — US disclosed
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2009-10-08 — — US disclosed
WO-2009124167-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
WO-2009124167-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
WO-2007070433-A2 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 CYP2D6 461/4885CYP2C19 387/4885CYP2C9 490/4885
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 CYP2D6 684/4885CYP2C19 1139/4885CYP2C9 2487/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 CYP2D6 536/4885CYP2C19 1042/4885CYP2C9 2176/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 CYP2D6 684/4885CYP2C19 1139/4885CYP2C9 2487/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 CYP2D6 536/4885CYP2C19 1042/4885CYP2C9 2176/4885
US-20100286191-A1 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators CXCR3, CXCR1, CXCR2 CYP2D6 1650/4885CYP2C19 1788/4885CYP2C9 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.